Relapse after omalizumab discontinuation in chronic spontaneous urticaria

BACKGROUND: Post-cessation relapse is difficult to compare because patient selection, outcome definitions and observation periods vary. OBJECTIVE: To synthesize relapse after omalizumab cessation in CSU and CSU-predominant cohorts and examine interpretive limitations. METHODS: We updated searches in PubMed, Embase, Scopus and Web of Science on 23 October 2026. Source-defined clinical relapse after complete cessation was separated from taper failure and retreatment. Random-effects logit pooling and sensitivity analyses addressed population, response, follow-up, overlapping reports and statistical models. RESULTS: = 87.7%; prediction interval 16.0-79.9%). CSU-only pooling gave 47.1% (95% CI 40.2-54.2%). Results reflect different follow-up periods, not a common time-specific risk. Eighty-three candidate full reports were unavailable. Three newly verified small risk sets contributed 0/1, 0/2 and 3/5 outcomes; excluding sets with fewer than ten stoppers yielded 46.3%. Pure dose reduction was supported by one observational arm. Confirmed type IIb-specific relapse counts were unavailable. CONCLUSION: Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.

Authors

Institutions

Publication Details

Journal
Cutaneous and Ocular Toxicology
Published
2026-11-12
DOI
https://doi.org/10.1080/15569527.2026.2760909
Primary Topic
Urticaria and Related Conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Relapse after omalizumab discontinuation in chronic spontaneous urticaria

Esranur Ünal, Muhammed Burak Yücel
Cutaneous and Ocular Toxicology
Urticaria and Related Conditions
article

Relapse after omalizumab discontinuation in chronic spontaneous urticaria

Esranur Ünal, Muhammed Burak Yücel
article en

Abstract

BACKGROUND: Post-cessation relapse is difficult to compare because patient selection, outcome definitions and observation periods vary. OBJECTIVE: To synthesize relapse after omalizumab cessation in CSU and CSU-predominant cohorts and examine interpretive limitations. METHODS: We updated searches in PubMed, Embase, Scopus and Web of Science on 23 October 2026. Source-defined clinical relapse after complete cessation was separated from taper failure and retreatment. Random-effects logit pooling and sensitivity analyses addressed population, response, follow-up, overlapping reports and statistical models. RESULTS: = 87.7%; prediction interval 16.0-79.9%). CSU-only pooling gave 47.1% (95% CI 40.2-54.2%). Results reflect different follow-up periods, not a common time-specific risk. Eighty-three candidate full reports were unavailable. Three newly verified small risk sets contributed 0/1, 0/2 and 3/5 outcomes; excluding sets with fewer than ten stoppers yielded 46.3%. Pure dose reduction was supported by one observational arm. Confirmed type IIb-specific relapse counts were unavailable. CONCLUSION: Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.

Cutaneous and Ocular Toxicology
Ufuk University (TR)
Good health and well-being
Urticaria and Related Conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon